A group of enzymes known as nitric oxide synthases (NOSs) are responsible for producing nitric oxide (NO) from L-arginine. L-arginine is oxidized to produce NO and L-citrulline by NO synthases. Neuronal NOS (nNOS), inducible NOS (iNOS), and endothelial NOS (eNOS) are the three NOS isoforms found in mammals. Numerous physiological processes in the nervous, immune, and cardiovascular systems involve NO produced by these various NOS isoforms. Pathologic conditions such as stroke, inflammation, and hypertension can result from uncontrolled NO production. As a result, isoform-specific NOS inhibitors have a lot of potential as therapeutic treatments for diseases linked to NO.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V75149 | (+)-Hannokinol | 408324-76-5 | (+)-Hannokinol can be extracted from the fruits of AMOMUM TSAO-KO (Zingiberaceae). | |
V84404 | (+)-Rhododendrol ((S)-(+)-Rhododendrol; (+)-Betuligenol) | 59092-94-3 | ||
V75146 | (-)-10,11-Dihydroxyfarnesol | 37133-76-9 | (-)-10,11-Dihydroxyfarnesol is a compound extracted from the endophytic fungus Cryptomarasmius aucubae. | |
V101873 | (2R)-6-Methoxynaringenin | 1212075-61-0 | (2R)-6-methoxynaringenin is the R-form of 6-methoxynaringenin. | |
V71565 | (Rac)-Zevaquenabant ((Rac)-MRI-1867) | 1610420-28-4 | (Rac)-Zevaquenabant ((Rac)-MRI-1867, compound 6b) is a CB1R/iNOS dual-targeting inhibitor (antagonist) with a Ki of 5.7 nM for CB1R. | |
V77363 | (Rac)-ZLc-002 | (Rac)-ZLc-002 is an inhibitor (blocker/antagonist) of the interaction between nNOS and nitric oxide synthase 1 adapter protein (NOS1AP), inhibits inflammatory pain and chemotherapy-induced neuropathic pain, and synergizes with Paclitaxel to reduce tumor cell viability. | ||
V75092 | (S)-ZLc002 | 308277-46-5 | (S)-ZLc002 is the S-enantiomer of ZLc-002. | |
V102009 | 1,3-PBIT dihydrobromide | 200716-66-1 | 1,3-PBIT is a potent inhibitor of iNOS with a Ki value of 47 nM, while the Ki values for eNOS and nNOS in purified human enzymes are 9 and 0.25 μM, respectively. | |
V90910 | 1-Heptadecanoyl-rac-glycerol | 5638-14-2 | 1-Heptadecanoyl-rac-glycerol (1-Heptadecanoin) is a glyceride compound with anti-inflammatory activity. | |
V84184 | 1400W (W1400) | 180001-34-7 | 1400W is a slow, tight binding, highly selective inducible nitric oxide synthase (iNOS) inhibitor | |
V96926 | 2′-Hydroxy-2,3-dimethoxychalcone | 42220-80-4 | α-Gracinoic acid is a chalcone derivative with anti-inflammatory activity. | |
V5303 | NQN-1 (PPM-18) | 65240-86-0 | NQN-1 (PPM-18), a chemically synthesized naphthoquinone derivative and an anti-inflammatory agent, is a novel, potent and cell-permeable and anti-inflammatory agent shown to express inhibitory effects of iNOS through the blocking of NF kappa B activationin vitro. | |
V83602 | 3,4-DAA | 2117759-07-4 | ||
V75095 | 3-Amino-1,2,4-triazine | 1120-99-6 | 3-Amino-1,2,4-triazine is a NO synthase inhibitor and can also inhibit the secretion of nitrite. | |
V75119 | 3-O-Acetyl-16α-hydroxydehydrotrametenolic acid | 168293-14-9 | 3-O-Acetyl-16α-hydroxydehydrotrametenolic acid is a triterpenoid with anti~inflammatory activity. | |
V75125 | 5,7,8-Trimethoxyflavone (Norwogonin 5,7,8-trimethyl ether) | 23050-38-6 | 5,7,8-Trimethoxyflavone (Norwogonin 5,7,8-trimethyl ether) comes from Andrographis paniculata and can inhibit NO with IC50 of 39.1 μM. | |
V75135 | 6-Methoxynaringenin | 94942-49-1 | 6-Methoxynaringenin is a naturally occurring flavonoid that can inhibit NO production with IC50 of 25.8 μM. | |
V92174 | 8-Nitroguanine | 168701-80-2 | 8-Nitroguanine is a product of DNA nitration damage caused by reactive nitrogen species and may be a potential biomarker for the progression of malignant fibrous histiocytoma. | |
V75122 | 8A8 | 2766594-12-9 | 8A8 is a potent inhibitor of the pro-inflammatory factor NO with IC50 of 4.7 μM. | |
V75152 | 9-Hydroxy-α-lapachone (α-Dihydrocaryopterone) | 22333-58-0 | 9-Hydroxy-α-lapachone (α-DiHydrocaryopterone) is a natural phenol that potently inhibits LPS-induced NO production in RAW 264.7 cells with IC50 of 4.64 µM. |